- Two Antidepressants No Better Than One?
- Increased CV Risk With Varenicline: New Meta-Analysis
- What Future for Niacin After AIM-HIGH?
- Supply of Medically Necessary Drugs Dwindling
- CMS to Pay for Provenge for Metastatic Prostate Cancer
- UK NICE Gives Preliminary Nod to Ticagrelor
- Institute of Medicine Issues Blueprint for Pain in America
- Nation's Prescription Drug Abuse Problem Continues to Grow
- TZD Use May Increase Risk for Diabetic Macular Edema
- Preventive Efforts in Type 2 Diabetes Are Cost Effective
- Recall of Pain, Headache Meds Because of Label Mix-Up
- US Prevalence of Diabetic Kidney Disease Rising
- FDA Approving Cancer Drugs Faster Than Europe
- Experts Warn U.S. to Boost Alzheimer's Funding
- Pharmacists Taking a More Active Role in Patient Care
- Supreme Court Overturns Ban on Prescription Data Mining
- Study Rekindles Cancer-ARB Question, This Time in Diabetics
- Telaprevir and Peginterferon-Ribavirin Improve HCV Outcomes
- Risperidone Recalled Due to Possible Contamination
- Nilotinib Beats Imatinib at 24 Months in Treatment of CML
- Indomethacin for Injection Vials Recalled
- FDA Approves Test to Determine HER2 Status in Breast Cancer
- Medication Error Prevention: A Shared Responsibility
- Glaucoma Medication Costs Rising Significantly
- FDA Warns of Serious Risks Associated With Liraglutide
- Outraged Politicians Demand Gout Drug Price Probe
- Prior Therapy Doesn't Compromise Teriflunomide's MS Benefit
- Interferon Delays Progression to Multiple Sclerosis
- Promoting Adherence to Oral Chemotherapy
- New DSM-5 to Go Electronic
- Affordable Care Available for Multiple Sclerosis Patients
- Azilsartan/Chlorthalidone Combo Bests Olmesartan/HCTZ
- Belimumab Shows Sustained Benefits in SLE
- Medicare Must Fix Geographic Payment System, IOM Report Says
- Lifelong Antiretroviral Therapy Unsustainable, Experts Say
- Antibiotics Overused in Children With Asthma
- E-Prescribing Penalty Could Hit Up to 109,000 Clinicians
- High Survival Rate With Natalizumab-Associated PML
- Did Sanofi Pay Petitioners to Help Delay Generic Lovenox?
- Switching to Aripiprazole May Reduce Metabolic Risk
- Management of Acute Pain After Hip Fracture
- New NLA Guidelines on the Management of Patients With FH
- Broad-Spectrum Antibiotic Use on the Rise
- FDA Tells Advisors to Focus on ACCORD for Fenofibrate Review
- Can Diabetes Meds Treat Depression?
- Internet Tied to Growth in U.S. Prescription Drug Abuse
- Opioid Monitoring Lax and Inconsistent, Study Finds
- New Dosing Guidelines for Kids' Liquid Medicines
- AF Patients Are $26 Billion/Year More Costly to the US
- Bevacizumab Comparable in Safety to Ranibizumab at 2 Years
- FREEDOM Trial: Long-Term Denosumab Safe, Efficacious for BMD
- Avastin as Effective as Costlier Lucentis for AMD
- New Diabetes Guidelines Address Gap in Comprehensive Care
- Medicare Quality Bonuses More Than Doubled in 2010
- FDA's Long-Awaited Opioid Plan Includes Mandatory Education
- U.S. Republicans Regroup on Medicare, Budget Plan
- Elderly Hypertensive Patients Benefit From Treatment: ACC/AHA
- The 10 Most Prescribed Drugs
- Nine Drugs Added to FDA Watch List
- Provenge: The Straw That Broke Medicare Part B's Back?
- Thousands of Bottles of Topiramate Recalled Due to 'Musty' Odor
- New AACE Diabetes Guidelines Emphasize Individualized Care Plans
- Possible Link Between SSRIs and Breast, Ovarian Cancer
- HCV Burden on US Healthcare System Increasing
- Dabigatran 150 Mg Twice Daily Effective in All Types of AF
- Government Shutdown Averted by Last-Minute Budget Deal
- Expand Role of New Oral Health Professionals: IOM Report
- Senate Bill to Put Physician's Medicare Billing Data Online
- Similar Clinical Outcomes With ARB, CCB for HTN in Diabetics
- High-Dose Opioid Prescribing Directly Boosts Death Risk
- Ipilimumab Is for Community-Based Oncologists Too, Says Expert
- What's Hot at AAN 2011?
- Ipilimumab Risk Strategy Released by FDA
- Fast Track for Cancer Drugs: Shut It Down or Speed It Up?
- Proposed GOP 2012 Budget Turns Medicare Into Subsidy Program
- US Report on Status of Cancer: 'Still a Long Way to Go'
- New Doubts on Value of Prostate Cancer Screening
- More Data on Diabetes Risk With Statins
- Johnson & Johnson Recalls Even More Tylenol
- ESRD From Lupus Nephritis Increasing in Certain Groups
- FDA Says Pharmacies Can Still Compound Generic Makena
- Why Aren't AHA/ACC Guidelines Writers All Conflict-Free?
- Meta-Analysis Confirms Efficacy of Biological Therapy for IBD
- Top Metro Hospitals Ranked by US News & World Report
- Irinotecan Lots Recalled Because of Contamination
- Alternative Agents No Safer Than Atypicals in the Elderly
- Healthcare Reform a Work in Progress, Say Medical Societies
- OnabotulinumtoxinA Reduces Urinary Incontinence
- Online Follow-up Reduces Depression, Boosts Therapy Adherence
- More Damning Data on Rosiglitazone
- Antidepressants Linked to Glaucoma in Elderly
- NCCN Tweaks 2011 Multiple Myeloma Guidelines
- Blue Shield Calif. Withdraws Planned Rate Hikes
- New Blood Conservation Guidelines on Antiplatelet Therapy
- Questions Remain About Belimumab in Certain Lupus Patient Groups
- Morphine/Naltrexone Combo Withdrawn
- NCCN Continues to Modify Prostate Cancer Guidelines
- Myeloid Growth Factor Risks and Benefits Updated in NCCN Guideline
- Second-Generation TKIs Join Imatinib as Front-Line Treatment for CML
- Head and Neck Cancer Guidelines 'Streamlined'
- Breast Cancer Guideline Updated at 2011 NCCN
- Quality of Cancer Care Falling With Doc Shortages and Rising Costs
- Number of Cancer Survivors in US Continues to Increase
- Physicians Face 29.5% Medicare Pay Cut in 2012
- J&J Animas Unit Recalls Leaky Insulin Cartridges
- US Breast Cancer Rates No Longer Falling
- One-Quarter of US Adults Had Hypertension in 2008
- UN Decries Poor Access to Pain Relief
- Designer Drug Abuse out of Control: UN Drugs Board
- New Changes to Cancer Guidelines at NCCN 2011
- FDA Pulls Unapproved Cold, Cough, Allergy Drugs From Market
- Expanding Medicaid Will Cost US States Billions-Study
- FDA Grants Hearing on Bevacizumab for Breast Cancer
- Long-Term Use of Bisphosphonates Increases Risk for Atypical Fractures
- Largest Study to Date Shows Little Need for PSA Beyond 10 Years Postop
- One Lot of Warfarin Recalled
- Dabigatran Joins US Atrial-Fib Guidelines
- Threshold for 'High Risk' Reduced in New AHA Guidance on CVD Prevention for Women
- Research on Botulinum Toxin for Migraine 'Unconvincing'
- Obama's New Budget Proposes 2-Year 'Doc Fix'
- Intrathecal Baclofen 'Underutilized' for MS Spasticity: Report
- More Cancer Centers Publishing Survival Data
- FDA Adds 13 Drugs to Watch List
- Early Warning System for Prescription Drug Shortages
- Pradaxa in Bottles Must Be Used Within 30 Days
- Diagnosis and Treatment of Gout Reviewed
- Updated BPH Treatment Guideline Released
- AAP Issues Recommended Childhood and Teen Immunization Schedules
- Lifetime Risk for RA Much Higher Than Expected
- Recommendations on Use of Meningococcal Conjugate Vaccines Updated
- Oncologists Must Discuss All Options in Advanced Cancer: ASCO Policy
- Dutasteride Not Approved for Prostate Cancer Prevention
- CDC: 26 Million Americans Have Diabetes
- Cost of Cardiovascular Disease to Triple by 2030
- Using ACE Inhibitors Instead of ARBs Could Save Millions, Say Canadian Docs
- ACIP Updates Guidelines for Use of Antiviral Agents for Influenza
- US Physicians Fear Healthcare Reform: Thomson Reuters Survey
- Sorafenib Effective in Resistant GIST
- US Task Force Releases Updated Osteoporosis Screening Recommendations
- Bevacizumab in Breast Cancer: Genentech Submits Response to FDA
- Dronedarone Linked to Severe Liver Injury
- ACIP Updates Guidelines for Use of Tdap Vaccine
- Cost of Cancer in the United States to Go Up, Up, Up
- FDA Still Evaluating Insulin Glargine and Possible Cancer Risk
- FDA Limits Acetaminophen in Prescription Analgesics
- Macular Degeneration Decreasing in the United States
- Fatal Medication Errors Seen With High-Dose Morphine Oral Solution
- IDSA Issues First Guidelines for Treatment of MRSA
- Albuterol Inhalation Solution Recalled Due to Mislabeling
- Registration for EHR Bonuses Begins January 3
- GlaxoSmithKline Offers UK Rebate If Pfizer Cancer Drug Better
- Flu Activity Remains Low in Most US Regions
- Seven Lots of Dexamethasone Injection Recalled
- FDA Warns of Possible Increased Risk for Death With Somatropin
- Abbott Recalls Millions of Diabetic Test Strips
- Top Medical Centers Join Forces on Comparative Effectiveness Research
- New Legislation Creates First National Action Plan for Alzheimer's Disease
- CDC Issues 2010 Treatment Guidelines for Sexually Transmitted Diseases
- FDA Rescinds Approval of Bevacizumab for Metastatic Breast Cancer
- Copays Undermining Aromatase Inhibitors? Yes, But . . .
- Sublingual Immunotherapy May Be Safe, Effective for Allergic Rhinitis
- AZURE: Zolendronic Acid Effect on Breast Cancer Is Complicated
- Anakinra Effective for Severe Muckle-Wells Syndrome
- Experts Mull Dabigatran vs Warfarin for Stroke Prevention in AF
- FDA Approves 60-Second HIV Test
- Ongoing Drug Shortages Hitting Oncology Hardest
- New Guidelines on Primary Stroke Prevention From AHA/ASA
- FDA Advisors Nix Proscar, Avodart Prevention Claims
- CDC Releases New Guidance for the 2010-2011 Influenza Season
- Wide Variation in Response to FDA Rosiglitazone Warning
- Major and Notable Cancer Advances in 2010
- Management of BPH and Prostate Cancer Reviewed
- Biogen Reports 5 New Cases of PML With Natalizumab
- Provenge Fares OK at CMS Review
- General Satisfaction With Direct-to-Consumer Genetic Testing Kits
- Asthma Care Poor in the United States
- Denosumab Superior to Zoledronic Acid in Advanced Breast Cancer
- Physicians, Consumers Need Better Understanding of Genetic Testing
- Dronedarone Safety Assailed in Nonprofit Group Report
- PPIs and Antiplatelets: New Consensus Document
- Phenytoin Injection Should Stay on the Market, FDA Panels Recommend
- Dabigatran Q&A: The Who, When, and How for Switching, Starting, and Stopping the New Oral Anticoagulant
- Pharmacotherapy for Fibromyalgia, Pain, and Depression: An Expert Interview With Laura A. Morgan, PharmD, BCPS
- CDC Panel Recommends Changes to 2011 Immunization Schedules
- On the Congress Floor: Specialists Debate New Oral Agents for MS
- Sandoz Recalls Methotrexate Vials That May Contain Glass Flakes
- Meta-Analysis Shows Reduced Colorectal Cancer Rates Among Statin Users
- New Guidelines Recommend Caution in Using ESAs in Cancer Patients
- Financial Impact of Electronic Health Record Use Is Considerable
- Diabetes Could Surge in U.S. by 2050
- Fentanyl Transdermal System Lots Recalled
- Drug Companies Influence Prescribing, Study Finds
- UnitedHealth Tests Global Fee for Chemotherapy
- 11-Year WHI Data Show Increase in More Advanced Breast Cancers
- 2010 AHA Guidelines: The ABCs of CPR Rearranged to "CAB"
- FDA Advisory Panel Supports Continued Use of Darbepoetin: No Label Changes Proposed
- FDA Clears Anti-CCP Test for Rheumatoid Arthritis
- Novartis Announces Availability of Fingolimod Support Programs
- FDA Clears Rapid RSV Dipstick Test
- Atorvastatin Recall Due to 'Uncharacteristic Odor"
- One Fifth of Americans Have Arthritis, Survey Shows
- "A Very Complex, Difficult History for the Agency": The FDA on Rosiglitazone
- New Published Guidance on Hypertension in Blacks Meets Criticism
- Growth Hormone for Cystic Fibrosis May Cut Hospitalizations: Meta-Analysis
- AAP Issues New Guidelines for Management of Iron Deficiency
- Bristol-Myers Recalls Avalide Drug Samples
- JUPITER Criticism Addressed Again in More Detail
- Recession Pushes Many Into U.S. Healthcare Plan
- Nearly 1 in 10 US Adults Meets Criteria for Current Depression
- Cost-Effectiveness of Statins in Low-Risk Populations
- Lots of Epogen and Procrit Recalled Due to Glass Flakes in Vials
- FDA Restricts Rosiglitazone; EMA Pulls the Plug
- Psychotropic Polypharmacy Increasingly Common in Pediatric Outpatient Practice
- NCCN Offers "Very Sophisticated Tools" to Patients
- Telephone Care-Management Program Reduces Healthcare Costs
- U.S. Democrats Unveil Global Drug Safety Bill
- U.S. Medicare Advantage Premiums to Dip in 2011
- More U.S. Doctors Moving to E-Prescriptions: Report
- Global Alzheimer's Disease Costs to Top $600 Billion in 2010
- U.S. FDA Panel Urges Wider Use for Addiction Drug
- FDA Delays Decision on Breast Cancer Indication for Bevacizumab
- FDA Advisors Say Sibutramine's CV Risks Warrant Harsher Restrictions or Withdrawal
- CMS Head Calls for Stakeholders to Come Together to Improve Healthcare Quality, Delivery, and Cost
- FDA Approves Pediatric Use of Protopam for Organophosphate Poisoning
- Prescription Drug Use on the Rise in U.S.
- Infantile Spasms Working Group Releases New Guidelines
- New Guidelines Issued for Insomnia and Other Sleep Disorders
- Guidelines Updated for Influenza Vaccination and Antiviral Therapy in Children
- Judge Declines to Stop Sales of Generic Lovenox; Cites Lower Cost
- FDA's Oversight Board Sees Growing Range of Drug Safety Issues
- Poll: Patients Unhappy With Rx Drugs
- Cancer Has Greater Economic Impact Than All Other Diseases
- Bevacizumab for Breast Cancer Hotly Debated
- FDA Panel Gives Mixed Blessing to Duloxetine for Chronic Pain
- Cost-Effectiveness of Trastuzumab in Gastric Cancer Questioned
- Drug Information From Pharmacies Found Lacking
- FDA Recommends Withdrawal of Midodrine
- FDA Planning Final Opioid Recommendations by 2011
- Caveats and Concerns With New Study on Hormone Therapy and Breast Cancer
- US, States Work to Shut Down Fake Healthcare Plans
- Bisphosphonates Not Linked to Esophageal Cancer, Says Study
- US Health Overhaul Helps Medicare Prospects-Report
- More Than 70 Million US Adults Obese: US CDC
- Rare Diseases Lure Big Drugmakers
- RSV Prophylaxis Reduces Recurrent Wheezing in Nonatopic Preemies
- Comparative Effectiveness Research Flush With Federal Money
- ACIP Updates Guidelines for Prevention and Control of Influenza With Vaccines
- FDA Approves Flu Shot With H1N1 Protection for 2010-2011 Season
- Are Children Treated With TNF Blockers at Increased Cancer Risk?
- Sanofi-Aventis Sues FDA Over Generic Lovenox Approval